PCSK9 Activity Is Potentiated Through HDL Binding
Authors:
- Sean A. BurnapSBSean A. Burnap
- Katherine SattlerKSKatherine Sattler
- Raimund PechlanerRPRaimund Pechlaner
- Elisa DuregottiEDElisa Duregotti
- Ruifang LuRLRuifang Lu
- Konstantinos TheofilatosKTKonstantinos Theofilatos
- Kaloyan TakovKTKaloyan Takov
- Gerd HeuschGHGerd Heusch
- Sotirios TsimikasSTSotirios Tsimikas
- Carlos Fernández-HernandoCFCarlos Fernández-Hernando
- Sarah E. BerrySBSarah E. Berry
- Wendy L. HallWHWendy L. Hall
Open Access
- 12 November 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 129 (11) , 1039-1053
Abstract
Rationale: PCSK9 (proprotein convertase subtilisin/kexin type 9) circulates in a free and lipoprotein-bound form, yet the functional consequence of the association between PCSK9 and HDL (high-density lipoprotein) remains unexplored. Objective: This study sought to interrogate the novel relationship between PCSK9 and HDL in humans. Methods and Results: Comparing lipoprotein and apolipoprotein profiles by nuclear magnetic resonance spectroscopy and targeted mass spectrometry measurements with PCSK9 levels in the community-based Bruneck study (n=656) revealed a positive association of plasma PCSK9 with small HDL, alongside a highly significant positive correlation between plasma levels of PCSK9 and apolipoprotein C3 (apoC3), an inhibitor of lipoprotein lipase. The latter association was replicated in an independent cohort, the SAPHIR study (Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk; n=270). Thus, PCSK9-HDL association was determined during the postprandial response in two dietary studies (n=20 participants each, 8 time points). Peak triglyceride levels coincided with an attenuation of the PCSK9-HDL association, a loss of apoC3 from HDL, and lower levels of small HDL as measured by nuclear magnetic resonance spectroscopy. Crosslinking mass spectrometry upon isolated HDL identified PCSK9 as a potential HDL-binding partner. PCSK9 association with HDL was confirmed through size-exclusion chromatography and immuno-isolation. Quantitative proteomics upon HDL isolated from patients with coronary artery disease (n=172) returned PCSK9 as a core member of the HDL proteome. Combined interrogation of the HDL proteome and lipidome revealed a distinct cluster of PCSK9, phospholipid transfer protein, clusterin, and apolipoprotein E within the HDL proteome that was altered by sex and positively correlated with sphingomyelin content. Mechanistically, HDL facilitated PCSK9-mediated low-density lipoprotein receptor degradation and reduced low-density lipoprotein uptake through the modulation of PCSK9 internalization and multimerization. Conclusions: This study reports HDL as a binder of PCSK9 and regulator of its function. The combination of -omic technologies revealed postprandial lipemia as a driver of PCSK9 and apoC3 release from HDL. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03191513; URL: https://www.isrctn.com ; Unique identifier: ISRCTN20774126.Keywords
Funding Information
- British Heart Foundation (CH/16/3/32406)
- British Heart Foundation (RG/16/14/32397)
- Österreichische Forschungsförderungsgesellschaft (K-Project No. 843536)
- Österreichische Forschungsförderungsgesellschaft (COMET No. 868624)
- Fondation Leducq (18CVD02)
- Deutsche Forschungsgemeinschaft (SFB 1116)
This publication has 41 references indexed in Scilit:
- Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor DegradationJournal of Biological Chemistry, 2013
- Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose dietsNutrition & Metabolism, 2013
- High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering drugs and diet network (GOLDN): an interventional studyLipids in Health and Disease, 2011
- Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small ApolipoproteinsArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor DegradationJournal of Biological Chemistry, 2009
- Molecular basis for LDL receptor recognition by PCSK9Proceedings of the National Academy of Sciences, 2008
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading ActivityBiochemistry, 2008
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humansLipids in Health and Disease, 2008
- Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic miceJournal of Clinical Investigation, 2006
- Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.Journal of Clinical Investigation, 1986